TNF blockade in rheumatoid arthritis: Implications for therapy and pathogenesis
Tóm tắt
The role of the immune response in rheumatoid arthritis (RA) is a subject of debate, although it is widely believed to be a T‐cell‐driven disease. Progress is being hindered by lack of convincing evidence of a defined specific antigen initiating or perpetuating the response. Clinical trials using monoclonal antibodies directed against T‐cell surface molecules such as CD4, CD5, and CD7 have thus far not provided evidence of efficacy. The negative data may reflect inadequate dosing or could suggest that indiscriminate depletion of T cells is insufficient by itself as a therapeutic strategy. Blocking proinflammatory cytokines (e.g. TNFα, IL‐1) or augmenting anti‐inflammatory cytokines (e.g. IL‐10) offers an alternative approach to therapy. Clinical trials using monoclonal anti‐TNFα have been particularly successful in controlling inflammation and markedly reducing acute phase proteins and cellular ingress. However, because disease invariably relapses, repeated therapy is necessary. Preliminary experience suggests that this is possible. Anti‐TNF therapy for RA has defined a molecular target and new approach for treating immuno‐inflammatory disorders.
Từ khóa
Tài liệu tham khảo
Butler D. M., 1995, Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti‐TNFα antibody with the IL‐1 receptor antagonist, Eur. Cytokine Netw., 6, 225
Elliott M. J., 1995, Anti‐cytokine therapy in rheumatoid arthritis. Baillieres Clin, Rheumatol., 9, 633
Feldmann M., 1996, Annual Review of Immunology, 397
Feldmann M. Elliott M. J. Woody J. N.&Maini R. N.:Anti‐TNFα therapy of rheumatoid arthritis.Adv. Immunol1996.
Kirkham B. W., 1992, Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis, J. Rheumatol., 19, 1348
Maini R. N., 1995, Clinical response of rheumatoid arthritis (RA) to anti‐TNFα (cA2) monoclonal antibody (mAb) is related to administered dose and persistence of circulating antibody, Arthritis Rheum., 38, S186
Olsen N. J., 1994, Multicenter trial of an anti‐CD5 immuno‐conjugate in rheumatoid arthritis (RA), Arthritis Rheum., 37, S295
Piguet P. F., 1992, Evolution of collagen arthritis in mice is arrested by treatment with anti‐tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor, Immunology, 77, 510
Pincus T., 1993, What is the natural history of rheumatoid arthritis, Rheum. Dis. Clin. N.A., 19, 123, 10.1016/S0889-857X(21)00171-X